<DOC>
	<DOCNO>NCT01986010</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , immunogenicity various dos , formulation , rout administration Human Cytomegalovirus ( HCMV ) vaccine V160 administer 3-dose regimen healthy adult . Each treatment arm 10 participant accompany placebo arm 4 participant . The initial treatment arm HCMV seropositive participant receive V160 Low Dose without adjuvant intramuscular injection . Escalation V160 dose , inclusion adjuvant , administration intradermal injection , vaccination HCMV seronegative participant perform review safety data previous treatment arm . The purpose study identify vaccine formulation associate optimal safety profile HCMV-specific immune response evaluation subsequent clinical study V160 .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity Human Cytomegalovirus Vaccine ( V160 ) Healthy Adults ( V160-001 )</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Healthy base medical history physical examination Serologically confirm HCMV seronegative HCMV seropositive Agrees avoid unusual , unaccustomed strenuous , vigorous physical exercise/activity 72 hour 72 hour dose study vaccine Body weight ≥110 lb ( 50 kg ) body mass index ( BMI ) 19 32 kg/m^2 If reproductive potential , agree follow study 4 week last dose study vaccine : 1 ) practice abstinence heterosexual activity , 2 ) use partner use 2 allowable method birth control heterosexual activity Has previously receive cytomegalovirus vaccine Has history allergic reaction anaphylactic reaction vaccine component require medical intervention Has history severe allergic reaction require medical intervention Is pregnant breastfeed expect conceive 2 week study 1 month last dose study vaccine Plans donate egg sperm study start 1 month last dose study drug Has impairment immunologic function include , limited autoimmune disease , splenectomy , HIV/AIDS Received systemic corticosteroid ≥14 consecutive day complete treatment within 30 day study start Received immunosuppressive therapy include , limited rapamycin equivalent , tacrolimus , FK506 , fujimycin , therapy use solid organ/cell transplant , radiation therapy , immunosuppressive/cytotoxic chemotherapy , therapy know interfere immune response within 1 year study start Has condition repeat venipuncture injection pose minimal risk , hemophilia , thrombocytopenia severe coagulation disorder , significantly impaired venous access Has condition require active medical intervention monitoring diabetes mellitus , autoimmune disease , clinically significant chronic medical condition consider progressive Has history within past 5 year current drug alcohol abuse Has major psychiatric illness Is legally mentally incapacitate Has participate another clinical study past 4 week , plan present study participate treatmentbased study study invasive procedure perform Has receive valganciclovir , ganciclovir , valacyclovir , foscarnet , cidofovir 4 week prior 1 month follow V160 vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>